Sign in
Taking peoplePhase 1

Intravenous DNase I for the Treatment of Sepsis (IDEALSepsisI)

Key facts

Who runs it
McMaster University
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 1
People taking part
36 people, planned
Started
17 Jan 2023
Planned end
30 Sept 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Intravenous DNase I
Record updated
3 March 2026

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Age of ≥18 years
  • Admitted to the ICU in the last 48 hours
  • Suspected or proven infection as the admitting diagnosis
  • A sequential (sepsis) organ function assessment (SOFA) score of ≥2 above baseline
  • Expected to remain in the ICU for ≥ 72 hours

Who cannot take part

  • Have a significant risk of bleeding as evidenced by one of the following:; Surgery requiring general or spinal anesthesia within 24 hours before enrolment; The potential need for surgery in the next 24 hours; Evidence of active bleeding; A history of severe head trauma requiring hospitalization; Intracranial surgery, or stroke within three months before the study; Any history of intracerebral arteriovenous malformation, cerebral aneurysm, or mass lesions of the central nervous system; A history of congenital bleeding diatheses; Gastrointestinal bleeding within five weeks before the study unless corrective surgery had been performed; Trauma is considered to increase the risk of bleeding; Presence of an epidural catheter; Need for therapeutic anticoagulation
  • Receiving DNase I by inhalation
  • Have other forms of clinically apparent shock, including cardiogenic, obstructive (massive pulmonary embolism, cardiac tamponade, tension pneumothorax), hemorrhagic, neurogenic, or anaphylactic shock
  • Terminal illness with a life expectancy of fewer than three months
  • No consent/inability to obtain consent from a substitute decision-maker
  • Pregnant and/or breastfeeding

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 100 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Phase I dose-escalation safety and feasibility of IV DNase I in ICU septic patients.

The 2 groups in the trial

  • Intravenous DNase ITreatment being tested

    We will enroll up to 36 Participants; each is receiving repeated unit doses of DNase I, BID, delivered by IV infusion over 3 or 7 consecutive days (12 +/- 1 hour apart) according to the following dose-escalation schedule with up to 6 Participants per dose panel. * Panel 1: 25 µg/kg, BID for 3 days (cumulative dose: 150 µg/kg) * Panel 2: 25 µg/kg, BID for 7 days (cumulative dose: 350 µg/kg) * Panel 3: 125 µg/kg, BID for 3 days (cumulative dose: 750 µg/kg) * Panel 4: 125 µg/kg, BID for 7 days (cumulative dose: 1750 µg/kg)

  • ControlNo study treatment, for comparison

    We will also enroll 12 septic Participants who do not receive intravenous DNase I (as Comparator Group). These patients will be recruited contemporaneously based on the same inclusion and exclusion criteria.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intravenous DNase I for the Treatment of Sepsis: A Phase I Safety and Feasibility Study in ICU Patients
Criteria questions
Built from NCT05453695, who can take part
Publications
Record updated
3 March 2026